OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
January 18, 2022
Samsung Biologics is planning to construct a new manufacturing facility in Incheon, South Korea, that will offer multi-product manufacturing, including cell and gene therapies and next-gen vaccines.
January 17, 2022
Protective external packaging ensures COVID-19 vaccines arrive safely.
January 11, 2022
The agreeement will add to Merck KGaA’s LNP and mRNA capabilities.
The agreement expands Pfizer’s access to LNP formulation technology for mRNA vaccines and therapeutics.
January 05, 2022
With this investment into Yapan Bio, Piramal Pharma adds new technologies and capabilities in large molecules, including vaccines and gene therapies, to its global offering.
December 13, 2021
Fareva plans to use blow-fill-seal equipment and ApiJect’s prefilled injector technology to create fill/finish capacity in France.
December 09, 2021
Sanofi’s acquisition of Origimm Biotechnology will add to its pipeline of vaccine candidates for treating acne.
December 02, 2021
Lean delivery offers a promising solution to supply and manufacturing bottlenecks by integrating project teams early on and widening the team’s field of view.
November 29, 2021
Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp. have partnered to advance GreenLight’s mRNA COVID-19 vaccine candidate.
The companies are testing their existing vaccines against the new variant of concern and are pursuing variant-specific versions.